Bullish On Bavarian Nordic’s Vaccine Portfolio And Revenue Potential In 2025
Summary: Bavarian Nordic holds contracts totaling approximately $340 million for 2025, driven by vaccine demand and global...
Tag: BVNRY
Bavarian Nordic’s Mpox Moment Fades, But Diversification Shines
Summary: Bavarian Nordic’s mpox vaccine sales have declined post-outbreak, causing reduced revenue and highlighting its...
Mpox Stocks Have Popped, But Pickings Are Slim For The Discerning Investor
Summary: WHO has declared a public health emergency due to an upsurge of mpox in Africa, leading to a coordinated...
Bavarian Nordic: Jynneos Expansion Amid Global Health Emergencies
Summary: Bavarian Nordic specializes in vaccines for infectious diseases and immuno-oncology therapies, with Jynneos being...
Bavarian Nordic A/S Could Post A Strong Comeback
Summary: Bearish sentiment weighed heavily on the biotech industry and Bavarian Nordic A/S.There is reason for optimism...
Bavarian Nordic: A Stock You Should Not Miss In 2017
Summary: Bavarian Nordic has projected a strong year-over-year revenue growth for 2017.Stockpiling target of the US...